Details of a Researcher - Fujimoto Yukari

Fujimoto Yukari

写真a

Affiliation: Faculty of Science and Technology, Department of Chemistry (Yagami)

Position: Professor

Related Websites

https://chem.keio.ac.jp/fujimoto-lab/english/

Page Top ▲

Career 【 Display / hide 】

1989.04

-

1998

Sumitomo Chemical Co., Ltd., Research Chemist
1998.08

-

2001.03

Department of Chemistry, Columbia University, Research Associate
2002.04

-

2003.02

Nagoya University, Postdoctoral Researcher
2003.03

-

2006.05

Osaka University, Assistant Professor
2006.05

-

2008.02

Osaka University, Associate Professor (Koushi)

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

1985.04

-

1989.03

Osaka University, Facluty of science, Department of Chemistry

University, Graduated
2002.03

Osaka University, Ph. D.

Graduate School, Other

Page Top ▲

Research Areas 【 Display / hide 】

Nanotechnology/Materials / Bio chemistry
Nanotechnology/Materials / Chemistry and chemical methodology of biomolecules
Life Science / Bioorganic chemistry

Page Top ▲

Research Keywords 【 Display / hide 】

Bioorganic Chemistry, Glycochemistry, Chemistry for Natural Products, Chemical Biology

Page Top ▲

Research Themes 【 Display / hide 】

Investigation of biofunctional system by utilizing organic chemistry,

1998.08

-

Present

Page Top ▲

Books 【 Display / hide 】

(Natural product chemistry II ~Gift from nature)

Yukari Fujimoto, Tokyo Kagaku Dojin, 2018
Glycoscience: Basic Science to Applications

Yukari Fujimoto, The Japan Consortium for Glycobiology and Glycotechnology, 2018
“Sugar Synthesis by Microfluidic Techniques” In Glycochemical Synthesis : Strategies and Applications

Fukase, K., Tanaka, K., Fujimoto, Y., Shimoyama, A., Manabe, Y., John Wiley & Sons, 2016
"Microbial glycoconjugates recognition with tlrs and nlrs in innate immunity" In Glycoscience: Biology and Medicine

Yukari Fujimoto, Koichi Fukase, Springer Japan, 2015
「糖鎖の新機能開発・応用ハンドブック～創薬・医療からヘルスケアまで」第4編　糖鎖の工学—合成・機能, 第2章　糖鎖合成（化学合成）と機能, ７.免疫増強複合糖質

Yukari Fujimoto, エヌ・ティー・エス, 2015

display all >>

Page Top ▲

Papers 【 Display / hide 】

The key entity of a DCAR agonist, phosphatidylinositol mannoside Ac₁PIM₁: Its synthesis and immunomodulatory function

Arai Y., Torigoe S., Matsumaru T., Yamasaki S., Fujimoto Y.

Organic and Biomolecular Chemistry 18 ( 19 ) 3659 - 3663 2020.05

Accepted, ISSN 14770520

　View Summary

© The Royal Society of Chemistry 2020. Ac1PIM1is a potential biosynthetic intermediate for phosphatidylinositol mannosides (PIMs) fromMycobacterium tuberculosis. We achieved the first synthesis of Ac1PIM1by utilizing an allyl-type protecting group strategy and regioselective phosphorylation of inositol. A very potent agonist of an innate immune receptor DCAR, which is better than previously known agonists, is demonstrated.
- Access to Document (DOI)
Design and Discovery of Covalent α-GalCer Derivatives as Potent CD1d Ligands

Kishi J., Inuki S., Kashiwabara E., Suzuki T., Dohmae N., Fujimoto Y.

ACS Chemical Biology 15 ( 2 ) 353 - 359 2020.02

Accepted, ISSN 15548929

　View Summary

© 2020 American Chemical Society. CD1d is a nonpolymorphic antigen-presenting protein responsible for the regulation of natural killer T (NKT) cell activation. α-Galactosyl ceramide (α-GalCer, KRN7000) is the representative CD1d ligand that can bind to the CD1d protein. The resulting complex is recognized by the T cell receptors of the NKT cell, inducing various immune responses. Previous structure-activity relationship studies of α-GalCer have revealed that the ability of NKT cells to induce cytokines depends on the ligand structure, and in particular, ligands that form more stable complexes with CD1d display potent activity. We focused on the Cys residue of the large hydrophobic pockets of CD1d (A′ pocket) and developed α-GalCer derivatives containing groups that can form covalent bonds. The assay results revealed that these ligands displayed higher levels of cytokine production and Th2 cell-type cytokine polarization response. Furthermore, the LC-MS/MS analysis indicated that the chloroacetylamide-containing ligand was covalently bound to Cys12 of CD1d, which suggests that the enhanced activities result from the formation of a stable CD1d-ligand complex. To our knowledge, this is the first ligand that allows covalent bond formation to CD1d under physiological conditions.
- Access to Document (DOI)
Potent Th2 Cytokine-Bias of Natural Killer T Cell by CD1d Glycolipid Ligands Based on “Anchoring Effect” of Polar Groups in Their Lipid Component.

Inuki, S., Kashiwabara, E., Hirata, N., Kishi, J., Nabika, E., Fujimoto, Y.

Angew. Chem. Int. Ed. 57 ( 31 ) 9655 - 9659 2018

Research paper (scientific journal), Joint Work, Accepted, ISSN 14337851

　View Summary

© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Th2-biasing CD1d ligands are attractive potential candidates for adjuvants and therapeutic drugs. However, the number of potent ligands is limited, and their biasing mechanism remain unclear. Herein, a series of novel Th2-biasing CD1d glycolipid ligands, based on modification of their lipid part, have been identified. These have shown high binding affinities and efficient Th2 cytokine production. Importantly, the truncated acyl chain containing variants still retain their binding affinities and agonistic activities, which can be associated with an “anchoring effect,” that is, formation of a buried hydrogen bond between a polar group on the acyl chain and the CD1d lipid-binding pocket. The analysis indicated that the appearance rates of ligand–CD1d complexes on the cell surface were involved in Th2-biasing responses. The designed ligands, having the anchor in the shorter lipid part, are one of the most potent Th2-biasing ligands among the known ligands.
- Access to Document (DOI)
Syntheses and Immunological Evaluation of Self-Adjuvanting Clustered N-Acetyl and N-Propionyl Sialyl-Tn Combined with A T-helper Cell Epitope as Antitumor Vaccine Candidates.

Chang, T. C., Manabe, Y., Fujimoto, Y., Ohshima, S., Kametani, Y., Kabayama, K., Nimura, Y., Lin, C. C., Fukase, K.

Angew. Chem. Int. Ed. (Angewandte Chemie - International Edition) 57 ( 27 ) 8219 - 8224 2018

Research paper (scientific journal), Joint Work, ISSN 14337851

　View Summary

© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Sialyl-Tn (STn) is a tumor-associated carbohydrate antigen (TACA) rarely observed on healthy tissues. We synthesized two fully synthetic N-acetyl and N-propionyl STn trimer (triSTn) vaccines possessing a T-helper epitope and a TLR2 agonist, since the clustered STn antigens are highly expressed on many cancer cells. Immunization of both vaccines in mice induced the anti-triSTn IgG antibodies, which recognized triSTn-expressing cell lines PANC-1 and HepG2. The N-propionyl triSTn vaccine induced the triSTn-specific IgGs, while IgGs induced by the N-acetyl triSTn vaccine were less specific. These results illustrated that N-propionyl triSTn is a valuable unnatural TACA for anticancer vaccines.
- Access to Document (DOI)
Isolated Polar Amino Acid Residues Modulate Lipid Binding in the Large Hydrophobic Cavity of CD1d

Inuki, S., Aiba, T., Hirata, N., Ichihara, O., Yoshidome, D., Kita, S., Maenaka, K., Fukase, K., Fujimoto, Y.

ACS Chem. Biol. 11 3132 - 3139 2016.09

Research paper (scientific journal), Accepted
- Access to Document (DOI)

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

“生物有機化学の交差点 ― 人との出会いが研究を深める”

藤本ゆかり

ドラマチック有機合成化学　感動の瞬間100　有機合成化学協会編 ( 化学同人) 198 - 199 2023.07
“脂質改変型CD1dリガンドの創製”

井貫晋輔，藤本ゆかり

月刊ファインケミカル (シーエムシー出版) 51 ( 12 ) 12 - 17 2023
“細菌由来糖ヘプトース誘導体の合成-新たに発見された自然免疫活性化機構”

藤本ゆかり，井貫晋輔

化学 (化学同人) 74 ( 1 ) 68 - 69 2019
“第1部　教育・研究関連のしごと,　大学教員（実験系）”

藤本ゆかり

化学のしごと図鑑　近畿化学協会編 (化学同人近畿化学協会編) 8 - 11 2019
“免疫活性物質としてのリポ多糖とその化学合成”

藤本ゆかり

医学のあゆみ『リポ多糖とその受容体のフロンティア』 (医歯薬出版株式会社) 253 ( 11 ) 1073 - 1076 2015

display all >>

Page Top ▲

Presentations 【 Display / hide 】

Glycolipids; Synthesis and immunomodulatory functions as lipid antigens

Yukari Fujimoto

The International Chemical Congress of Pacific Basin Societies 2021 (Pacifichem 2021) (Online) ,

2021.12
,
Oral presentation (invited, special)
Synthesis and immunomodulatory activities of microbial glycoconjugates containing phosphatidyl inositol

Yukari Fujimoto

The International Chemical Congress of Pacific Basin Societies 2021 (Pacifichem 2021) (Online) ,

2021.12
,
Oral presentation (invited, special)
Glycoconjugates as immune modulators

Yukari Fujimoto

16th meeting of the International Endotoxin and innate immunity society/The 7th International Symposium on Middle Molecular Strategy (ISMMS-7) (Kobe/ Online) ,

2021.10
,
Oral presentation (invited, special)
Glycoconjugates as immune modulators

Yukari Fujimoto

Asian Carbohydrate Chemistry and Glycobiology Webinar (Online) ,

2021.09
,
Oral presentation (invited, special)
Immunomodulatory glycolipids: synthesis and modulation of cytokine-biasing responses

Yukari Fujimoto

American Chemical Society (ACS) Spring 2021 (Online) ,

2021.04
,
Oral presentation (invited, special)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

免疫調節性複合脂質の合成・機能の理解と展開

2021.04

-

2025.03

MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A) , Principal investigator
ネオ・セルフ脂質抗原分子ライブラリ構築と免疫調節機能解析

2019.04

-

2021.03

MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research on Innovative Areas, Principal investigator
免疫機構の複合的な機能制御を可能とする中分子化合物の創製

2018.04

-

2020.03

MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research on Innovative Areas, Principal investigator
革新的中分子創薬技術の開発／先端的な中分子創薬関連技術の開発

2018

-

2021.03

Japan Agency for Medical Research and Development (AMED), 次世代治療・診断実現のための創薬基盤技術開発事業, Yukari Fujimoto, No Setting
生体防御に関わる脂質認識機構の理解と制御を指向した複合脂質合成と機能解明

2017.04

-

2020.03

MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Principal investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

化合物、化合物の塩、神経機能調節物質、神経機能調節物質の評価方法、化合物の製造方法、及び化合物の塩の製造方法

Date applied：特願2020-535822 2019.08

Patent, Joint
化合物又はその塩、ナチュラルキラーT細胞活性化剤、及び医薬組成物

Date applied： PCT/JP2017/008381 2017

Patent, Joint
化合物又はその塩、ナチュラルキラーT細胞活性化剤、及び医薬組成物

Date applied：特願2016- 57416 2016.03

Patent, Joint
トール様受容体４活性化作用を有するフニクロシン誘導体及びその用途

Date applied：特願2014-201593 2014

Date issued：特許番号6359409号 2018

Patent, Joint
Novel immunostimulatory molecules

Date applied： PCT/EP2015/072292 2015

Patent, Joint

display all >>

Page Top ▲

Awards 【 Display / hide 】

有機合成化学協会企業冠賞

2021.02

Type of Award： Award from Japanese society, conference, symposium, etc.
Nagase Foundation Award

2016.04
Osaka University Presidential Awards for Achievement

2013.08, Osaka University
The Alois Nowotny Award

2012.10, International Endotoxin & Innate Immunity Society
BCSJ award（Bulletin of the Chemical Society of Japan award）

2008.07, The Chemical Society of Japan